Category Archives: Press Releases

Binosto® Persistence and Efficacy Safety Data to be Presented at the ASBMR 2018 Congress in Montréal, Canada

FREIENBACH, Switzerland–(BUSINESS WIRE)–EffRx Pharmaceuticals SA is proud to announce that recent data from a standardized clinical database suggest an improved safety and tolerability profile of Binosto® (alendronate effervescent tablets) over conventional alendronate tablets in postmenopausal women with osteoporosis, translating into higher treatment persistence of patients. Binosto was also found to be as effective as traditional alendronate tablets based on assessment of bone mineral density scores and bone turnover markers. read more

https://www.businesswire.com/news/home/20180926005351/en/Binosto®-Persistence-Efficacy-Safety-Data-Presented-ASBMR

 

Binosto Data to be Presented at the WCO-IOF-ESCEO Congress in Krakow, Poland, Held from April 19th to 22nd, 2018

EffRx Pharmaceuticals SA is proud to announce that it will participate in the World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases in Krakow, Poland, from 19 to 22 April 2018. The WCO-IOF-ESCEO Congress, as it is also known, is the world’s leading clinical conference on bone, joint and muscle health and therefore the ideal venue for EffRx to showcase its flagship product Binosto, the world’s first and only buffered soluble alendronate for the treatment of postmenopausal osteoporosis. Medical professionals from around the world will be able to learn more about Binosto and its exciting properties at the Binosto booth in the exhibition area of the ICE Krakow congress center (booth #21).

EffRx Pharmaceuticals SA is equally thrilled to inform that new Binosto data pertaining to its efficacy and persistence will be presented at the WCO-IOF-ESCEO Congress. The data will be presented in the poster area on Saturday, 21 April 2018, from 14:00 to 15:00 (posters #853 and #857).

Binosto®, the world’s first and only buffered soluble alendronate for the treatment of osteoporosis, was developed with the aim to capitalize on the excellent efficacy profile of alendronate sodium while improving gastrointestinal tolerability. Upper gastrointestinal side effects are known to be problematic with tablet forms of alendronate sodium as well as of other bisphosphonates.

Please join EffRx at the WCO-IOF-ESCEO Congress in Krakow!

European market-entry strategy for biopharma companies

The European pharmaceutical market offers many opportunities for U.S. biopharmaceutical companies. An early engagement as well as a visceral understanding of the heterogeneity of the European market are key to succeed. Partnering with EffRx Pharmaceuticals, a commercial-stage pharmaceutical company offers various advantages. Because of its diversity and non-bureaucratic access to a talented workforce, EffRx an ideal partner to kick off your international go-to-market strategy.

For the entire article please go to the Greater Zürich Area.

Binosto Data Presented at the ASBMR Congress in Denver

EffRx Pharmaceuticals SA is proud to inform that the latest safety data on Binosto® were presented as a poster on Sunday, 10th of September 2017 at the American Society for Bone and Mineral Research (ASBMR) 2017 Annual Meeting in Denver, Colorado, USA attended by more than 3,000 scientists from 70 countries.

Binosto®, the world’s first and only buffered soluble alendronate for the treatment of osteoporosis, was developed with the aim to capitalize on the excellent efficacy profile of alendronate sodium while improving gastrointestinal tolerability. Upper gastrointestinal side effects are known to be problematic with tablet forms of alendronate sodium as well as of other bisphosphonates.

The authors of the ASBMR publication concluded that Binosto is associated with a lower frequency of upper gastrointestinal side effects than reported for tablet forms of alendronate sodium.

“This is an important milestone for EffRx as the post-marketing safety data support our hypothesis that the unique Binosto properties have a positive impact on incidence of upper gastrointestinal side effects,” says Dr. Josef Hruska, the first author and Executive Medical Director at EffRx Pharmaceuticals. He further states, “The reduction of upper gastrointestinal side effects will potentially lead to increased adherence which in turn results in realizing full antifracture efficacy.”

The Abstract will be published by the Journal of Bone Mineral Research.

About EffRx Pharmaceuticals SA

EffRx Pharmaceuticals SA is a Swiss-based commercial-stage pharmaceutical company developing and commercializing prescription medications for specialty indications. Our lead commercialized product, Binosto® (buffered soluble alendronate 70 mg) is indicated for the treatment of osteoporosis and marketed in US, Europe and Asia. We strive to address true unmet medical needs and provide improved outcomes to patients with musculoskeletal, genitourinary and endocrine disorders.

About Binosto®

Binosto® (alendronate 70 mg effervescent tablets) is the first and only buffered solution for the treatment of osteoporosis with proven antifracture efficacy. The buffered solution minimizes the possibility of exposing the esophagus (in case of reflux) and the stomach to acidified alendronate and thus reducing the risk of upper gastrointestinal toxicity.1,2 In the EU, Binosto® is approved for the treatment of postmenopausal osteoporosis. It is taken once a week as an easy-to-swallow, buffered solution with no risk of a tablet getting lodged in the esophagus. Binosto® has the potential to improve long-term patient adherence to therapy, thereby decreasing the risk of disabling fractures.

Disclaimer

Please refer to the official Binosto® prescribing information and approved indications, contraindications, and warnings in your country.

References:

  1. Hodges LA et al. Modulation of gastric pH by a buffered soluble effervescent formulation: A possible means of improving gastric tolerability of alendronate. International Journal of Pharmaceutics 2012;432:57-62.
  2. Binosto 70mg SPC. www.mhra.gov.uk; accessed 19.9.2017

 Media Contact: Pamela Saredi, psaredi@effrx.com

 

Osteoporosis patients in Germany and Russia get access to Binosto®

EffRx launches Binosto® the first and only buffered solution for the treatment of osteoporosis – in two more markets.

Freienbach, Switzerland, 8. June 2017 – EffRx Pharmaceuticals SA today announced that physicians in Germany and Russia treating patients with postmenopausal osteoporosis have a new therapy option: buffered soluble alendronate (Binosto®). This novel formulation, which is already available in eleven countries worldwide, provides gold-standard fracture risk reduction and offers the potential for enhanced gastric tolerability.1

In Germany, Binosto® is marketed by Recordati Pharma GmbH and in Russia by Polypharm. For EffRx Pharmaceuticals SA, who has developed Binosto®, the launch in Germany and Russia marks another important milestone. “With the addition of these two major markets, our geographic footprint grows significantly,” says EffRx Commercial Director Michael Schmid. “We are happy to have selected two strong and renowned local partners. While the growth of Binosto® in our existing markets remains high, geographic expansion through strong local partnerships continues to be a key priority for EffRx to bring the promise of Binosto® to patients worldwide.”

Data presented at the recent WCO-IOF-ESCEO Congress and published in Osteoporosis International suggest that Binosto® is associated with a lower frequency of upper gastrointestinal adverse reactions than reported for conventional alendronate tablets.2 “These data support the hypothesis that Binosto with its unique properties does enhance gastrointestinal tolerability,” says Dr. Josef Hruska, Medical Director. He adds, “This in turn may lead to improved compliance and persistence which are known to be problematic with conventional bisphosphonate tablets.”

About EffRx Pharmaceuticals SA

EffRx Pharmaceuticals SA is a Swiss-based commercial-stage pharmaceutical company developing and commercializing prescription medications for specialty indications. Our lead commercialized product, Binosto® (buffered soluble alendronate 70mg) is indicated for the treatment of osteoporosis and marketed in US, Europe and Asia. We strive to address true unmet medical needs and provide improved outcomes to patients with musculoskeletal, genitourinary and endocrine disorders.

About Binosto®

Binosto® (alendronate 70 mg effervescent tablets) – the first and only buffered solution for the treatment of osteoporosis – delivers gold-standard fracture risk reduction and offers the potential to improve adherence to therapy. Buffering minimizes the possibility of exposing the esophagus (in case of reflux) and the stomach to acidified alendronate.1 In the EU, Binosto® is approved for the treatment of postmenopausal osteoporosis. It is taken once a week as an easy-to-swallow, buffered solution with no risk of a tablet getting lodged in the esophagus. Binosto® has the potential to improve long-term patient adherence to therapy, thereby decreasing the risk of disabling fractures.

Disclaimer

Please refer to the official Binosto® prescribing information and approved indications, contraindications, and warnings in your country. Please click here for the approved SmPC in Europe.

References:

  1. Hodges LA et al. Modulation of gastric pH by a buffered soluble effervescent formulation: A possible means of improving gastric tolerability of alendronate. International Journal of Pharmaceutics 2012;432:57-62.
  2. Hruska J et al. Upper gastrointestinal safety with the buffered solution of alendronate 70 mg: post-marketing experience. Osteoporos Int 2017;28(S1):P589. http://www.wco-iof-esceo.org/sites/wco17/pdf/WCO17-AbstractBook.pdf.

Media Contact: Pamela Saredi, psaredi@effrx.com

Paolo Agnoluzzi Appointed CFO of EffRx Pharmaceuticals

Freienbach, Switzerland, June 1st, 2017 – EffRx Pharmaceuticals SA announced today the appointment of Mr. Paolo Agnoluzzi as Chief Financial Officer effective June 1st, 2017. Mr. Agnoluzzi joined EffRx in August 2016 as Interim Chief Financial Officer and led the re-organization of the Finance Department. Among other achievements he executed a number of debt and equity transactions, including a capital increase.

Mr. Agnoluzzi brings over 30 years of international financial experience, predominantly in biopharmaceutical companies. Most recently, he served as Finance Director for VistaJet Group. His responsibilities included acting as deputy CFO, leading the financial planning and analysis group, heading the treasury function and directing special projects within Finance. Previously, Mr. Agnoluzzi held the position of Director Finance Europe and Commercial Head DACH Region at Endocyte Europe GmbH. Prior to Endocyte, he spent more than 20 years at Amgen Europe/International driving its early European set-up of Amgen and serving various senior financial positions, including among others, Head of EU Finance Oncology, Bone & New Products and Director Finance & Administration.

“Mr. Agnoluzzi joins at an exciting and important stage in EffRx’s journey towards integrated multi-product pharmaceutical company. Paolo’s significant breadth and depth of financial and accounting expertise will be a major asset to expand the business of our company, building on Binosto® success,” said Mr. Lorenzo Bosisio, CEO of EffRx. “I want to express my genuine appreciation for his hard work, dedication and leadership over the past year in championing EffRx transformation. I wish him all the best for this well-earned promotion.”

Mr. Agnoluzzi commented, “I believe the potential for growth and value creation is tremendous, given the smart and passionate people in the Company and its attractive international footprint. I am confident that we can develop and execute plans to drive consistent sales growth. I am very excited.”

 

About EffRx Pharmaceuticals

EffRx Pharmaceuticals SA is a Swiss-based commercial-stage pharmaceutical company developing and commercializing prescription medications for specialty indications. Our lead commercialized product, Binosto® (buffered soluble alendronate 70mg) is indicated for the treatment of osteoporosis and marketed in US, Europe and Asia. We strive to address true unmet medical needs and provide improved outcomes to patients with musculoskeletal, genitourinary and endocrine disorders.

Bone markers as screening strategy for patient adherence to osteoporosis medications

IOF-ECTS Position Paper provides recommendations for the screening of adherence to oral bisphosphonates; proposes assessment using PINP and CTX bone turnover markers (BTMs) at baseline and after three months.

Oral bisphosphonates are common first line treatments for osteoporosis. However, approximately half of patients who begin osteoporosis treatment do not follow their prescribed treatment and/or discontinue treatment within a year. Identifying low adherence to medication – a problem commonly seen with many chronic diseases – is a critical issue as it jeopardizes the efficacy of treatment, leaving osteoporosis patients unprotected against fractures.

For the complete news story, visit the International Osteoporosis Foundation online.

 

 

Lorenzo Bosisio Appointed CEO of EffRx Pharmaceuticals

Freienbach, Switzerland, October 11th, 2016 – EffRx Pharmaceuticals SA announced that the Company has made some changes and additions to its management team.

Lorenzo Bosisio has been appointed as Chief Executive Officer effective July 1st, 2016. Prior to his promotion to CEO, Mr. Bosisio served as Chief Commercial Officer since 2013. During his tenure in EffRx, he has built the commercial infrastructure from the ground, successfully launched the Company’s lead product, Binosto®, enabling the transformation of EffRx from a drug development company to an integrated biopharmaceutical company with an international footprint.

Mr. Bosisio brings significant strategic and operational leadership experience from senior positions at Amgen, Alexion, PwC, and Tissot Medical. He has an excellent track record in building new international operations and brands as well as driving transformational growth in biopharmaceutical companies.

“I am highly satisfied with this appointment. Mr. Bosisio has exactly the right cross-functional experience and the right mindset to lead the expansion of our core franchise and to generate new business development opportunities.” said Mr. Jonas Ekblom, Chairman of EffRx.

Mr. Bosisio commented, “It has been a challenging and rewarding journey to bring EffRx to what it is today. I look forward to seeing further success and to leading EffRx through the next stage of its development”.

The company also announced that Mr. Paolo Agnoluzzi will serve as interim CFO, Dr. Josef Hruska has taken on the role as Medical / Medical Affairs Director and that Mr. Michael Schmid has joined as International Marketing Director.

About EffRx Pharmaceuticals

EffRx Pharmaceuticals is an innovative specialty pharmaceutical company that develops and commercializes novel therapeutic entities for specialty indications by applying its proprietary technology platform. EffRx developments focus at improving the quality of life of patients with unmet medical needs.

About Binosto®

Binosto® – the first and only alendronate buffered solution for the treatment of osteoporosis – delivers gold standard fracture-risk reduction and offers the potential to improve adherence to therapy. Buffering minimizes the possibility of exposing the oesophagus (in case of reflux) and the stomach to acidified alendronate1. Binosto® is taken once a week as an easy-to-swallow, buffered solution with no risk of a tablet getting lodged in the oesophagus. Binosto® has the potential to improve long-term patient adherence to therapy, thereby decreasing the risk of disabling fractures.

Disclaimer

Please refer to the official Binosto® Prescribing Information and approved indications, contraindications, and warnings in your country.

1Approved SmPC in Europe: http://www.mhra.gov.uk/home/groups/spcpil/documents/spcpil/con1447998343651.pdf

 

 

EffRx Announces Changes in the Composition of the Board of Directors

Freienbach, June 14th, 2016 — EffRx Pharmaceuticals SA, a specialty pharmaceutical company focused on the development of novel therapeutic entities for orphan and specialty indications, today announced the appointment of Dr. Jonas Ekblom as Chairman and Dr. Alcide Barberis as Member of the Board of Directors.

“I feel elated to join the Board of this exciting company and I look forward to working with the Management team and the Board of Directors as we progress EffRx into its next phase of consolidation, maturation and growth,” commented Dr. Jonas Ekblom, Chairman.

Dr. Ekblom and Dr. Barberis will be replacing Mr. Oscar Ahlgren, Mr. Carl-Gustaf Johansson and Mr. Thomas Mårtensson who have stepped down from their current role as Directors. During their tenure they have successfully managed the transition of EffRx to become an integrated pharmaceutical company with its flagship program, Binosto®, being now commercialized in 10 key countries across Europe, Asia and America. Mr. Anders Wiklund will continue to serve as a Board Director and with his accomplished industry experience will ensure a smooth transition within the Board.

Dr. Jonas Ekblom brings over 20 years of experience from the life science sector, with a focus in pharmacology and drug development. He has managed R&D programs in in several therapeutic areas. Dr. Ekblom has business experience from US, EU and Asia.

Dr. Alcide Barberis is a biotech entrepreneur and manager with over 20 years management experience in the biotechnology industry and scientific experience in the private and public research sectors.

 

Internis launches GI friendly alendronate formulation

PharmaTimes, May 20, 2016 — Internis Pharma Binosto is now widely available across the UK, offering patients with osteoporosis the chance to access the first buffered formulation of alendronate designed to minimise gastrointestinal side effects commonly linked with traditional versions of the drug.

The National Institute for Health and Clinical Excellence recommends alendronate as an option for the prevention of first fractures in a number of groups who have a high risk of fracture, as long-term treatment with the drug is known to improve bone mineral density (from 2.4 percent to 8.8 percent) and cut the risk of fracture (from 12 percent to 49 percent).

However, the side effects of the drug has led to poor compliance rates, with nine out of ten patients who are taking traditional form of alendronate having to drop therapy as a result. Eighty percent of patients come off treatment in the first year and over one in three fail to pick up a second indication, largely because of the gastrointestinal effects associated with bisphosphonates like alendronate.

Osteoporosis is estimated to affect more than three million people in the UK, most of whom are only aware they have it when they break a bone. Addressing poor adherence to treatment has been a key goal for some time, as it is estimated to result in a 37 percent higher risk of hospitalisation and a 17 percent higher risk of fracture, the firm notes.

Binosto’s novel, buffered alendronate formulation dissolves in water, helping to overcome the difficulties in swallowing pills that some patients experience and, crucially, as it increases pH levels in the stomach, thus minimising the gastrointestinal side effects commonly linked to these medicines, it has the potential to boost adherence.

The cost is £22.80 for four once-weekly tablets. This is a higher purchase price than a generic alendronate tablet but is lower than alternative treatments for patients who fail on alendronate (such as denosumab, etc). A spokesperson for the firm told PharmaTimes that Binosto should “save considerably on downstream costs”, given its potential to improve adherence and reduce the incidence of osteoporotic fracture, which costs the NHS around £5 million per day or £2 billion per year.

“I believe that, over time, data will show that Binosto’s novel alendronate formulation helps to improve the longterm tolerability of alendronate and helps to ensure that more women with osteoporosis are properly treated. This could result in fewer fractures, improved patient quality of life and lower overall costs,” said Dr Andrew Pearson, consultant radiologist, NHS Borders, commenting on its potential.

This impact will be more significant as our ageing population grows therefore, it is essential that patients have access to effective treatments that they are able to take over many years,” added Internis’ chief operating officer Paul Tredwell.

www.pharmatimes.com/news/internis_launches_gi_friendly_alendronate_formulation_1025980